{
  "id": 16577033,
  "title": "Could new US investment curbs complicate China’s biotech licensing surge?",
  "url": "https://urgent.news/2026/10/26/could-new-us-investment-curbs-complicate-chinas-biotech-licensing-16577033",
  "topic": "world",
  "section": "World",
  "published": "2026-10-26T08:00:23.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/article/3372151/could-new-us-investment-curbs-complicate-chinas-biotech-licensing-surge"
  },
  "original_language": "en",
  "account": null,
  "summary": "Chinese biotech firms face fresh headwinds in their global expansion as Washington’s proposed outbound investment restrictions threaten to disrupt deal structures, even though drug licensing agreements remain untouched for now, analysts say. The US Treasury Department’s draft rules released last week would “make it much harder for Chinese biotech firms to attract direct US investment or enter…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "FXStreet",
        "title": "China warns of countermeasures over expanded US investment curbs on biotech",
        "url": "https://urgent.news/2026/10/26/china-warns-of-countermeasures-over-expanded-us-investment-curbs-on",
        "published": "2026-10-26T00:40:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}